Measles is a highly contagious disease which is a significant
cause of mortality and morbidity worldwide. The time between
epidemics increased as vaccinations increased and the
age for having the disease increased, whereas measles
epidemics used to occur every 2-3 years in the prevaccination
era. Although there is a reliable and effective vaccination
program against measles, children who do not get the vaccine,
or who cannot form sufficient level of antibodies with a
single vaccine dose, remain susceptible to measles, which, in
turn,causes the measles virus to be pandemic. Sensitivity to
measles in school-age children is high, and school epidemics
have an important role in measles outbreaks.
The age at which the administration of measles vaccine is performed
is determined according to the age at which children
lose maternal antibodies transferred from their mothers. This
critical agevaries from society to society. Due to the low rate of
vaccination in under developed or developing countries, the antibodies
passing from the mother disappear early, and routine
measles vaccination is madeat 6 or 9 months of age. Due to the
higher vaccination rate in developed countries, the antibodies
passing from the mother disappear later, and routine measles
vaccination is performed at 12 or 15 months of age. However,
in both situationsa second dose of vaccine is necessary. The
American Advisory Committee on Immunization Practice [ACIP]
and the American Academy of Pediatrics [AAP] declare that 4-6
years of age is the ideal time for the second dose of vaccine,
and in most countries a second dose of measles, mumps, and
rubella [MMR] vaccine is given at this age.
The significant decrease in mortality and morbidity provided
by vaccinations confirms the success and significance of immunization
programs. Preventive antibody levels can be
measured serologically with various intervals after primary
vaccination in order to establish appropriate immunization
programs.
Due to immigration from neighboring southern countries, an
increase in measles cases has recently been identified in Turkey.
As measles cases have appearedin children of 4–6 years
of age who have not had their second dose of vaccine, it has
been suggested that the second measles vaccination be given
at the age of 4 years instead of 6-7 years when children
are in the first year of primary school. However, to our
knowledge, there is no comparative study investigating the
effectiveness of vaccinations at this age based on the serologic
measurement of preventive antibody levels. In this study
our aim, thus, was to measure the measles antibody levels of
children who have not yet had the second dose of measles
vaccine at 4 to 6 years of age. We have also evaluated the necessity
of a second dose of measles vaccine at 4 years of age
instead of 6 years of age in a period when the risk for measles
is increasing.
Linked Immunosorbent Assay (ELISA) method, and a measles
specific kit was used for this method. According to the suggestions
of the kit manufacturer, values of ≤10 IU/mL were
accepted as non-protective.
Statistical analysis of the data was performed using IBM SPSS
Statistics 18.0 software. Definitive statistical and Mann-Whitney
U tests were used for the evaluation of the mean value
of intragroup antibody levels and analysis of anthropometric
measurements and demographic data. A probability value less
than 0.05 (p<0.05) was accepted as statistically significant.
No comments:
Post a Comment